86 reports of this reaction
1.2% of all CINACALCET reports
#20 most reported adverse reaction
END STAGE RENAL DISEASE is the #20 most commonly reported adverse reaction for CINACALCET, manufactured by Amneal Pharmaceuticals LLC. There are 86 FDA adverse event reports linking CINACALCET to END STAGE RENAL DISEASE. This represents approximately 1.2% of all 7,231 adverse event reports for this drug.
Patients taking CINACALCET who experience end stage renal disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
END STAGE RENAL DISEASE is a less commonly reported adverse event for CINACALCET, but still significant enough to appear in the safety profile.
In addition to end stage renal disease, the following adverse reactions have been reported for CINACALCET:
The following drugs have also been linked to end stage renal disease in FDA adverse event reports:
END STAGE RENAL DISEASE has been reported as an adverse event in 86 FDA reports for CINACALCET. This does not prove causation, but indicates an association observed in post-market surveillance data.
END STAGE RENAL DISEASE accounts for approximately 1.2% of all adverse event reports for CINACALCET, making it a notable side effect.
If you experience end stage renal disease while taking CINACALCET, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.